Takhzyro Induces Rapid Resolution of Hereditary Angioedema Attacks, New Data Analysis Shows
Treatment with Takhzyro (lanadelumab) effectively reduces the number of attacks in patients with hereditary angioedema even in early phases of treatment, new analysis of data from the Phase 3 HELP study shows. Most recent trial results were shared in a poster, “Lanadelumab demonstrates rapid and sustained prevention of hereditary…